Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Rosaria Di Lorenzo, Paola Ferri, Michela Cameli, Sergio Rovesti & Chiara Piemonte. (2019) Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatric Disease and Treatment 15, pages 183-198.
Read now
Read now
Ilaria Cuomo, Georgios D Kotzalidis, Simone de Persis, Daria Piacentino, Filippo Perrini, Emanuela Amici & Sergio De Filippis. (2018) Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life. Neuropsychiatric Disease and Treatment 14, pages 1645-1656.
Read now
Read now
M. C. Mauri, A. Reggiori, S. Paletta, C. Di Pace & A. C. Altamura. (2017) Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Expert Opinion on Drug Safety 16:3, pages 365-379.
Read now
Read now
Articles from other publishers (7)
Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas & Javier Martínez. (2023) Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies. Annals of General Psychiatry 22:1.
Crossref
Crossref
Luis Gutiérrez‐Rojas, Sergio Sánchez-Alonso, Marta García Dorado & Paola M. López Rengel. (2022) Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 36:5, pages 517-527.
Crossref
Crossref
José Manuel Olivares & Andrea Fagiolini. (2022) Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis. Frontiers in Psychiatry 13.
Crossref
Crossref
Rosaria Di Lorenzo, Anita Iorio, Margherita Pinelli, Federica Maria Magarini, Mattia Marchi, Andrea Sacchetti, Chiara Calogero, Gian Galeazzi, Paola Ferri, Sergio Rovesti & Alessandro Minarini. (2022) Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs. Neuropsychiatric Disease and Treatment Volume 18, pages 829-846.
Crossref
Crossref
José Manuel Olivares, Ana González-Pinto & Mario Páramo. (2021) Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study. European Psychiatry 64:1.
Crossref
Crossref
Massimo Carlo Mauri, Alessandra Reggiori, Alessandro Minutillo, Gemma Franco, Chiara Di Pace, Silvia Paletta & Dario Cattaneo. (2020) Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the
Prophylaxis of Bipolar Disorder Type I with Manic Predominance. Pharmacopsychiatry 53:05, pages 209-219.
Crossref
Crossref
Esther Letícia Amorim Ribeiro, Tácio de Mendonça Lima, Marcio Eduardo Bergamini Vieira, Sílvia Storpirtis & Patricia Melo Aguiar. (2018) Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. European Journal of Clinical Pharmacology 74:10, pages 1215-1233.
Crossref
Crossref